 |
Warning Letters and Untitled Letters
to Pharmaceutical Companies
2008
These letters, sorted by month, are supplied by the CDER Freedom of Electronic
Information Office. This page only covers Division of Drug Marketing and Communications
and Headquarters Warning Letters. For District Office Warning Letters see the Main FDA FOI Warning Letters Page.
Some of the letters have been redacted or edited to remove confidential
information. Click on the month to view the letters in Adobe Acrobat format. [more...]
|
2008
[2007] [2006]
[2005]
[2004]
[2003]
[2002]
[2001]
[2000]
[1999]
[1998]
[1997] |
| May 2008 |
| Product/Issue |
Company/Individual |
Division |
Released |
Posted |
Fosrenol
|
Shire Development, Inc. |
Division of Drug Marketing,
Advertising, and Communications |
5/1/2008 |
5/8/2008 |
Trileptal (Warning Letter)
|
Novartis Pharmaceuticals Corporation |
Division of Drug Marketing,
Advertising, and Communications |
5/1/2008 |
5/8/2008 |
| April 2008 |
| Product/Issue |
Company/Individual |
Division |
Released |
Posted |
| Inspection (Warning Letter) |
Changzhou SPL Company, Ltd. |
Division of Manufacturing and Product Quality |
4/21/2008 |
4/21/2008 |
Peridex (Warning Letter)
|
Zila Pharmaceuticals, Inc. |
Division of Drug Marketing, Advertising, and Communications |
4/18/2008 |
4/22/2008 |
| Viagra (Warning Letter) |
Pfizer, Inc. |
Division of Drug Marketing,
Advertising, and Communications |
4/16/2008 |
4/21/2008 |
| March 2008 |
| Product/Issue |
Company/Individual |
Division |
Released |
Posted |
Avinza (Warning Letter)
|
King Pharmaceuticals, Inc. |
Division of Drug Marketing,
Advertising, and Communications |
3/24/2008 |
3/26/2008 |
| Clinical Investigation (Warning Letter) |
Saroj Brar, M.D. |
Division of Scientific Investigations |
3/20/2008 |
4/22/2008 |
| Clinical Investigation (Warning Letter) |
Ashok Shah, M.D. |
Division of Scientific Investigations |
3/19/2008 |
4/22/2008 |
| Clinical Investigation (Warning Letter) |
Frank Whittier, M.D. |
Division of Scientific Investigations |
3/6/2008 |
4/22/2008 |
| Inspection (Warning Letter) |
Coast Institutional Review Board |
Division or Scientific Investigations |
3/11/2008 |
3/26/2008 |
| February 2008 |
| Product/Issue |
Company/Individual |
Division |
Released |
Posted |
| BMIS Inspection (Warning Letter) |
Kevin W. Klein, M.D. |
Division or Scientific Investigations |
2/13/2008 |
2/28/2008 |
| Inspection (Warning Letter) |
West Jefferson Medical Center IRB |
Division or Scientific Investigations |
2/25/2008 |
4/1/2008 |
| January 2008 |
| Product/Issue |
Company/Individual |
Division |
Released |
Posted |
| BMIS Inspection (Warning Letter) |
Replidyne, Inc. |
Division or Scientific Investigations |
1/18/2008 |
2/15/2008 |
| Inspection (Warning Letter) |
Tomita Pharmaceutical Co., Ltd |
Division of Manufacturing and Product Quality |
1/14/2008 |
1/23/2008 |
Matters described in FDA warning letters may have been subject to subsequent
interaction between FDA and the recipient of the letter that may have changed the
regulatory status of the issues discussed in the letter. If you wish to obtain
available additional information on the current status of an issue in a particular warning
letter or notice of violation on this website, please contact the Agency or the recipient
of the letter directly. Inquiries to FDA should be sent to:
Food and Drug
Administration
Freedom of Information Staff (HFI-35)
5600 Fishers Lane, Rockville, MD
20857
Instructions for how to submit an FOI request can be found on the FDA FOI Page.
The letters are arranged in chronological order by month. Click on the product name to
view the letters in Adobe Acrobat (PDF) format. Go here for further information about Adobe Acrobat and download instructions.
Also see the "Cyber" Letters.
Back to Top Index
Date created: February 28, 2008; updated May 8, 2008 |
 |